Last reviewed · How we verify
Pingyangmycin Injection
Pingyangmycin is a bleomycin-type antibiotic that intercalates into DNA and causes strand breaks, leading to cell death.
Pingyangmycin is a bleomycin-type antibiotic that intercalates into DNA and causes strand breaks, leading to cell death. Used for Squamous cell carcinoma, Lymphoma, Head and neck cancer.
At a glance
| Generic name | Pingyangmycin Injection |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Bleomycin-type antibiotic chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Pingyangmycin is a glycopeptide antibiotic derived from Streptomyces pingyangensis that functions as a DNA-damaging agent. It binds to DNA and generates reactive oxygen species, causing double-strand breaks and inhibiting DNA synthesis. This mechanism makes it effective as a chemotherapeutic agent, particularly for squamous cell carcinomas and lymphomas.
Approved indications
- Squamous cell carcinoma
- Lymphoma
- Head and neck cancer
Common side effects
- Pulmonary toxicity/fibrosis
- Myelosuppression
- Mucositis
- Nausea and vomiting
- Alopecia
Key clinical trials
- A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts (PHASE4)
- Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: